Date	e:August 10, 2021		
	· Name: Hordur		
Man	uscript Title:_ Kirsten Ra	t Sarcoma (KRAS) Onco	gene Mutation Predicts Magnitude of Response and
Out	comes in Hepatic Arteri	al Infusion Pump Thera	py of Unresectable Colorectal Liver
Met	astases		
Man	uscript number (if known)	:	
relat parti to tra relat	ed to the content of your ies whose interests may be ansparency and does not i ionship/activity/interest,	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	
	following questions apply uscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th med In ite	e epidemiology of hyperte ication, even if that medic	ension, you should declare ation is not mentioned in to port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items, Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: pas	t 36 months
2	Grants or contracts from	_x_ None	r so months

any entity (if not indicated

x None

in item #1 above).

3

Royalties or licenses

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:	August 11, 2021
Your Nam	e: Randa Preihs
Manuscrip	t Title:_ Kirsten Rat Sarcoma (KRAS) Oncogene Mutation Predicts Magnitude of Response and
Outcome	s in Hepatic Arterial Infusion Pump Therapy of Unresectable Colorectal Liver
Metastas	es
	t number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None	
3	Royalties or licenses	_x_ None	

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:	August 11, 2021
Your Nam	e: Alexandra Bengel
	t Title:_ Kirsten Rat Sarcoma (KRAS) Oncogene Mutation Predicts Magnitude of Response and
Outcome	s in Hepatic Arterial Infusion Pump Therapy of Unresectable Colorectal Liver
Metastas	es
	t number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None	
3	Royalties or licenses	_x_ None	

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:	_August 11, 2021
Your Name	e: Sreenivasa Chandana
Manuscrip	t Title:_ Kirsten Rat Sarcoma (KRAS) Oncogene Mutation Predicts Magnitude of Response and
Outcomes	s in Hepatic Arterial Infusion Pump Therapy of Unresectable Colorectal Liver
Metastase	es
	t number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None	
3	Royalties or licenses	_x_ None	

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:	_August 11, 2021
Your Name	: M. Mura Assifi
Manuscript	t Title:_ Kirsten Rat Sarcoma (KRAS) Oncogene Mutation Predicts Magnitude of Response and
Outcomes	in Hepatic Arterial Infusion Pump Therapy of Unresectable Colorectal Liver
Metastase	es
	t number (if known):
-	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None	
3	Royalties or licenses	_x_ None	

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:August 11, 2021	
Your Name: Mathew Chung	
Manuscript Title: Kirsten Rat Sarcoma (KRAS) Oncogene Mutation	
Outcomes in Hepatic Arterial Infusion Pump Therapy of Unresect	table Colorectal Liver
Metastases	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None	
3	Royalties or licenses	_x_ None	

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations,	_x_ None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or	_x None	
	Advisory Board		
- 10			
10	Leadership or fiduciary role in other board, society,	_x_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical	_x_ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_x None	

Date:	_August 11, 2021
Your Name	: Gerald Paul Wright
Manuscript	t Title:_ Kirsten Rat Sarcoma (KRAS) Oncogene Mutation Predicts Magnitude of Response and
Outcomes	in Hepatic Arterial Infusion Pump Therapy of Unresectable Colorectal Liver
Metastase	es
	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_ None			
		Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_ None			
3	Royalties or licenses	_x_ None			

4	Consulting fees	_x_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_x_ None	
6	Payment for expert testimony	_x_ None	
7	Support for attending meetings and/or travel	_x_ None	
8	Patents planned, issued or pending	_x_ None	
_			
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x None	
- 10			
10	Leadership or fiduciary role in other board, society, committee or advocacy	_x_ None	
	group, paid or unpaid		
11	Stock or stock options	_x_ None	
	_		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x_ None	
13	Other financial or non- financial interests	_x None	